These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 10438343)
1. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. Fritz RS; Hayden FG; Calfee DP; Cass LM; Peng AW; Alvord WG; Strober W; Straus SE J Infect Dis; 1999 Sep; 180(3):586-93. PubMed ID: 10438343 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. Mäkelä MJ; Pauksens K; Rostila T; Fleming DM; Man CY; Keene ON; Webster A J Infect; 2000 Jan; 40(1):42-8. PubMed ID: 10762110 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Matsumoto K; Ogawa N; Nerome K; Numazaki Y; Kawakami Y; Shirato K; Arakawa M; Kudoh S; Shimokata K; Nakajima S; Yamakido M; Kashiwagi S; Nagatake T Antivir Ther; 1999; 4(2):61-8. PubMed ID: 10682150 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Calfee DP; Peng AW; Hussey EK; Lobo M; Hayden FG Antivir Ther; 1999; 4(3):143-9. PubMed ID: 12731753 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors. Höffken G; Gillissen A Med Microbiol Immunol; 2002 Dec; 191(3-4):169-73. PubMed ID: 12458354 [TBL] [Abstract][Full Text] [Related]
7. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. Hayden FG; Gubareva LV; Monto AS; Klein TC; Elliot MJ; Hammond JM; Sharp SJ; Ossi MJ; N Engl J Med; 2000 Nov; 343(18):1282-9. PubMed ID: 11058672 [TBL] [Abstract][Full Text] [Related]
8. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. Boivin G; Goyette N; Hardy I; Aoki F; Wagner A; Trottier S J Infect Dis; 2000 Apr; 181(4):1471-4. PubMed ID: 10762579 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. Monto AS; Fleming DM; Henry D; de Groot R; Makela M; Klein T; Elliott M; Keene ON; Man CY J Infect Dis; 1999 Aug; 180(2):254-61. PubMed ID: 10395837 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of inhaled zanamivir in the treatment and prevention of influenza]. Abad-Santos F; Gallego Sandín S; Novalbos Reina J; Martínez Sancho E; Gálvez Múgica MA An Med Interna; 2001 Feb; 18(2):93-9. PubMed ID: 11322008 [TBL] [Abstract][Full Text] [Related]
12. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Kaiser L; Henry D; Flack NP; Keene O; Hayden FG Clin Infect Dis; 2000 Mar; 30(3):587-9. PubMed ID: 10722450 [TBL] [Abstract][Full Text] [Related]
13. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. Hayden FG; Fritz R; Lobo MC; Alvord W; Strober W; Straus SE J Clin Invest; 1998 Feb; 101(3):643-9. PubMed ID: 9449698 [TBL] [Abstract][Full Text] [Related]
14. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. Walker JB; Hussey EK; Treanor JJ; Montalvo A; Hayden FG J Infect Dis; 1997 Dec; 176(6):1417-22. PubMed ID: 9395349 [TBL] [Abstract][Full Text] [Related]
15. Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice. Vogel GE Med Microbiol Immunol; 2002 Dec; 191(3-4):161-3. PubMed ID: 12458352 [TBL] [Abstract][Full Text] [Related]
16. Zanamivir: from drug design to the clinic. Elliott M Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388 [TBL] [Abstract][Full Text] [Related]
17. Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor. Eichelberger MC; Prince GA; Ottolini MG Virology; 2004 May; 322(2):300-7. PubMed ID: 15110527 [TBL] [Abstract][Full Text] [Related]
18. [symbol: see text] Zanamivir for influenza. Drug Ther Bull; 1999 Nov; 37(11):81-4. PubMed ID: 10696691 [TBL] [Abstract][Full Text] [Related]
19. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet; 1998 Dec; 352(9144):1877-81. PubMed ID: 9863784 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Calfee DP; Peng AW; Cass LM; Lobo M; Hayden FG Antimicrob Agents Chemother; 1999 Jul; 43(7):1616-20. PubMed ID: 10390212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]